ProxAI is a techbio company specializing in the development of first-in-class protein therapeutics by leveraging artificial intelligence to address hard-to-drug disease pathways. Our integrated solution features high-throughput cell-based screening assays to rapidly evaluate thousands of AI-designed protein binder sequences in a single, one-shot assay.